Julian Zachmann is an investment professional at ATHOS, where he focuses primarily on therapeutics spanning all development stages, modalities, and disease areas. 
 

After studying physics, he earned a PhD in computational drug discovery and contributed as a senior scientist at Ryvu Therapeutics. Completing his MBA, Julian shifted to venture investments at High-Tech Gründerfonds (HTGF) in 2019, and joined ATHOS in 2023. He is passionate about supporting entrepreneurs whose scientific breakthroughs have the potential to transform patients' lives.